SecBot SecBot

TRVI drug pipeline

Trevi Therapeutics, Inc. · 1 rated drug
$13.29
−2.6% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 bullish
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3
Time to marketIf Phase 3 trials succeed, a New Drug Application submission could occur in 2028-2029, with potential FDA approval and launch in 2029-2030 for the IPF chronic cough indication, assuming standard review timelines.

Haduvio nalbuphine extended-release Updated Nov 12

What to watch

The next major catalyst is topline data from the Phase 3 OCEAN-1 trial in IPF-related chronic cough, expected in 2027. Positive data would validate the Phase 2b signal and likely drive the stock toward the $28 mean analyst target; negative data would be a severe blow given Haduvio is Trevi's only pipeline asset. A Phase 2 start in non-IPF ILD chronic cough is planned for Q1 2027, and the cash runway into 2030 eliminates near-term financing risk.

Bull case
  • Haduvio met its primary endpoint in the Phase 2b CORAL trial (N=165) for IPF-related chronic cough, with results published in JAMA in January 2026, providing strong peer-reviewed validation of the mechanism.
  • GSK discontinued its rival chronic cough drug camlipixant in July 2026 after a Phase 3 failure, leaving Trevi as the only active developer in its three targeted chronic cough indications and removing a major competitive threat.
  • Analyst consensus is Strong Buy (17 Buy/Strong Buy, 1 Hold, 0 Sell) with a mean price target of $28.18, implying roughly 90% upside from the current $14.81 price; BMO Capital has a $36 target.
Bear case
  • Haduvio is an opioid-based therapy (kappa agonist / mu antagonist), which carries regulatory, abuse-liability and safety-perception risks that could limit commercial adoption or draw FDA scrutiny.
  • Phase 3 trials are inherently binary; positive Phase 2 data does not guarantee Phase 3 success, and the OCEAN-1/OCEAN-2 readouts in 2027-2028 are the only value-defining catalysts for this single-asset company.
  • Insider sales by director Michael Heffernan in September 2026 (about $594K total at ~$15/share, via a 10b5-1 plan) and institutional trims by Viking Global (-52% of position) and Citadel (full exit) in Q2 2026 signal some profit-taking near the stock's 52-week high.

Clinical trials

2 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
HaduvioCough Reduction in IPF With Nalbuphine ERPhase 2Completed · results165Apr 24, 2025
HaduvioRefractory Chronic Cough Improvement Via NAL ER (RIVER)Phase 2Completed · results66Jan 6, 2025